Regenerative medicine techniques in cardiovascular disease
Packer, Claire; Boddice, Beth; Simpson, Susan

DOI: 10.2217/rme.13.21

Citation for published version (Harvard):
Packer, C, Boddice, B & Simpson, S 2013, 'Regenerative medicine techniques in cardiovascular disease: where is the horizon?' Regenerative Medicine, vol 8, no. 3, pp. 351-360. DOI: 10.2217/rme.13.21

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
Regenerative medicine techniques in cardiovascular disease: where is the horizon?

Regenerative medicine techniques to restore cardiac and vascular function are being increasingly investigated as management options for cardiovascular disease. The authors set out to identify emerging regenerative techniques in cardiovascular disease and investigate their stage of development. The relevant networks in the field in the UK were contacted and online sources for cell therapy, tissue engineering, and other regenerative techniques and products were searched for online. A total of 49 Phase II, II/III and III trials of regenerative products or techniques were identified: 13 Phase III, eight Phase II/III and 28 Phase II trials. Twelve of the Phase III trials are for myocardial ischemia and involve an intracoronary infusion or intramyocardial injection of autologous bone marrow-derived stem cells. Most of those in Phase III trials are, however, associated either with an unproven delivery technique or cellular approach. The authors conclude that translation into clinical practice and diffusion into health systems is some way off.

Despite recent reductions in incidence and improvements in preventive and acute management, cardiovascular disease (CVD) remains responsible for significant health and social costs, and productivity losses. CVD, and in particular coronary artery disease, is also among the leading causes of death in many countries. Regenerative medicine techniques to restore cardiac and vascular function are being increasingly investigated as viable management options for CVD. The potential capacity of adult and embryonic stem cells to develop into cardiac stem cells, cardiomyocytes, vascular endothelial cells and smooth muscle cells; and to secrete cytokines and growth factors to support endogenous repair, is under evaluation [1,2]. In addition, developments in factor-based therapy to induce the body’s own regeneration processes via the action of paracrine factors, are also gaining attention as potential therapeutic options [1].

Support for progressing developments in regenerative medicine is gathering pace in a number of countries throughout Europe and the developed world [3–10]. The commitment to fund both basic science and translational research should mean that early research in regenerative medicine in CVD, which once appeared a distant vision, can be transformed into reality. In 2012, Praszek et al. deemed development of regenerative therapeutic strategies to reverse the progression of advanced heart failure one of the most urgent clinical needs of the 21st century, and concluded that an ideal cardiac regenerative therapy would involve a key cell type, a paracrine factor, a cardiac tissue niche and a safe, minimally invasive administration procedure to introduce the therapy to the affected area [11]. The choice of cell source is a fundamental question in cellular therapy. Using autologous cells may well be safe from adverse immune response, but has limitations, including the decline of regenerative capacity with age, the need for a collection procedure in people with serious underlying conditions and patient-to-patient variability in response [12]. In addition, although relatively costly, there are no intellectual property rights in the cell collection, isolation and reinfusion techniques, as they are generally standard procedures. Allogenic cells from younger, healthy donors have a higher regenerative potential than older autologous cells and cells from one donor can be used for more than one patient. Therefore, allogenic cells have a greater commercial value and the possibility of developing an ‘off-the-shelf’ product. However, although allogenic mesenchymal stromal cells, a subgroup of the bone-marrow derived mononuclear cells, are thought to be predominantly immunosuppressive, there are reports that such cells can switch from an immunomodulatory state (no generation of an immune response in the recipient) to an immunostimulant state with the potential to generate an immune response [13]. If this observation is confirmed then an immunosuppressive regimen may be required postimplantation, increasing the risks of adverse reactions.
The complete mechanism of action of stem and progenitor cell regeneration is uncertain, but does not appear to be solely operating through the replacement or regeneration of lost cells. There is evidence that infused stem cells induce paracrine cell-to-cell signaling, such as the production of cytokines or other factors, which may increase endogenous cellular repair and support increased collateral blood vessels [13]. An inverse relationship between benefit and cell dose administered has been reported and needs further elucidation [14]. An additional complicating factor for evaluation is the implantation method, which may have different efficacies for different patient groups. Current trials use either an intracoronary infusion or direct intramyocardial injection.

To date, there has been conflicting evidence on the ability of regenerative medicine techniques to improve ventricular function. In 2012, a Cochrane review updated evidence from 33 randomized, controlled trials (1765 participants) evaluating the effectiveness of autologous stem or progenitor cells to improve cardiac function in patients with acute myocardial infarction [15]. The authors found that cell therapy was not associated with statistically significant changes in the incidence of mortality (relative risk: 0.70; 95% CI: 0.40–1.21) or morbidity as measured by reinfarction, hospital readmission, restenosis and target vessel revascularization. However, despite the significant heterogeneity of the studies included, data demonstrated a short-term improvement in left ventricular ejection fraction (LVEF; weighted mean difference: 2.87%; 95% CI: 2.00–3.73) that was maintained over 12–61 months. The reviewers concluded that larger trials are required as well as standardization of methodology, cell dosing, formulation, timing of cell transplantation and patient selection.

In the work reported here, the authors identify and characterize emerging applications of regenerative medicine (stem cells and factor-based therapies) in development for the management of CVD and examine their stage of development for specific patient indications. This work was undertaken to inform health service policy- and decision-makers in England of key developments, in order that the development of national guidance can be undertaken in a timely fashion.

Methods
The authors undertook the initial searching for their review between June 2011 and January 2012, identifying key networks, organizations, experts and companies currently active in the regenerative medicine field. A list of commercial products known to be in development for CVD from the univerCellmarket database [101] was supplemented with a search of online sources (Box 1) to identify other regenerative techniques and products. Searches were updated in February 2013.

Medline was searched from 1996 to week 2 January 2012 (updated for clinical trials to week 5 February 2013). ClinicalTrials.gov searching was limited to trials first received between January 2001 and January 2012, with the status of Phase II and III trials updated in February 2013. The searches used a mix of medical subject headings and keywords including cardiac, heart, regenerative medicine, cardiovascular stem cell, cell therapy, tissue engineering and regeneration. The authors initially searched for any cell therapy, tissue engineering, and regenerative techniques and products being developed for any CVD indication in any clinical trial phase. We excluded any approaches or products that were in, or had reported results from, proof-of-concept or Phase I trials, but had no indication of ongoing Phase II trials.

For each identified approach or product thought to be in Phase II or III trials, or closer to licensing, the relevant commercial or academic institutes developing the technology were identified. Information was then collated about their approach, delivery method, specific clinical indication, ongoing trials and results from completed trials. The techniques found to be in Phase II, II/III and III trials are reported on here.

Results
The authors identified 49 Phase II, II/III or III clinical trials; a third in association with commercial developers (Figure 1). The majority of Phase II, II/III and III trials associated with industry are in development in the USA.

Three noncellular, factor-based therapies were identified: one in Phase III (adenovirus serotype-5 vector to deliver human fibroblast growth factor 4; trial 2; Table 1) and two in Phase II trials (FGF-1 and thymosin β-4; trials 17 and 21; Supplementary Table 1; see online www.future-medicine.com/doi/supp/10.2217/RME.13.21). The authors found two products using allogenic cells in Phase II trials (Revascor® and Prochymal®; trials 19 and 20; Supplementary Table 1). All the remaining trials reported using autologous cells that, except for three, were all derived from bone-marrow aspiration. Seven of the 12 cell-based Phase III trials used mononuclear cells, one used mesenchymal cells, one isolated and used CD34+ cells, two isolated and used CD133+...
cells in combination with coronary artery bypass grafting (CABG) and one transformed mesenchymal cells into cardiopoietic stem cells (C-Cure® from Cardio3 BioSciences, Belgium; trial 9; Table 1).

Clinical indications & delivery
Of the 13 Phase III trials, three are trials for refractory chronic angina; five for use in patients' postacute myocardial infarction (three in combination with CABG); three for ischemia-related heart failure; and two for dilated cardiomyopathy from other causes. Of the Phase III trials, eight involve, or will involve, an intramyocardial or transmyocardial injection, and five an intracoronary infusion.

Of the 36 Phase II/III and II trials (Supplementary Tables 1 & 2), one is for ischemic stroke, four for nonischemic dilated cardiomyopathy, three for refractory angina, 16 for use following acute myocardial infarction, and the rest for ischemic cardiomyopathy and heart failure. Delivery is by intramyocardial injection or intracoronary infusion for all trials except one allogenic product and one factor-based product, which are delivered intravenously (Prochymal, thymosin β-4; trials 20 and 21; Supplementary Table 1), and the trial in ischemic stroke (trial 18; Supplementary Table 1), which uses an intracarotid administration.

Phase III trials
Refractory angina
CD34+ autologous bone marrow-derived stem cell therapy (Baxter Healthcare Corporation, IL, USA), in development for the treatment of refractory angina, recently entered a Phase III trial. CD34+ cells are a subset of mesenchymal stem cells and are thought to be involved in the creation of new blood vessels and increased tissue perfusion. The RENEW Phase III trial [102] aims to enroll 450 patients across the USA and will compare intramyocardial delivery of CD34+ autologous cells harvested after G-CSF mobilization and apheresis with standard care or placebo. The trial is expected to last up to 24 months and has a primary end point of exercise tolerance at 12 months. Secondary end points include frequency of angina episodes and major cardiac events. In a Phase II trial involving 167 patients with refractory angina, those who received a low dose of CD34+ cells had significantly fewer episodes of angina per week at 6 months than those in the control group (6.8 vs 10.9 episodes; p = 0.02) [16]. Weekly angina episodes were also less frequent in the high-dose CD34+ group but the difference was not significant. Improvement in exercise tolerance at 6 months was also significantly greater in the low-dose group than in the placebo group (mean ± standard deviation (SD): 139 ± 151 vs 69 ± 122 s; p = 0.014), and greater, but not significantly in the high-dose group.

Alferminogene tadenovec (Generx™; Cardium Therapeutics, CA, USA) uses an adenovirus serotype-5 vector to deliver human FGF-4, which induces structural and physiological changes in the heart including the growth of new collateral blood vessels. Alferminogene tadenovec is entering a Phase III trial (ASPIRE) in 100 patients with stable angina who are symptomatic despite optimal medical therapy and who have a reversible perfusion defect of >9%
Table 1. Cellular and factor-based therapies in Phase III clinical trials.

<table>
<thead>
<tr>
<th>No.</th>
<th>Company or research unit</th>
<th>Therapy</th>
<th>Therapy type</th>
<th>Delivery</th>
<th>Indication(s)</th>
<th>Additional Phase III trial information</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Baxter Healthcare Corporation, IL, USA</td>
<td>CD34+ stem cells</td>
<td>Autologous CD34+ endothelial progenitor cell G-CSF mobilization and apheresis</td>
<td>Targeted intramyocardial injection</td>
<td>Refractory angina, not suitable for revascularization</td>
<td>RENEW (NCT01508910) has enrolled 416 participants from the USA and Canada. Cell delivery in ten intramyocardial injections. Final data collection is expected in June 2016 [102].</td>
</tr>
<tr>
<td>2</td>
<td>Cardium Therapeutics, CA, USA</td>
<td>Generx™ adenovirus serotype 5-mediated human FGF-4 gene transfer (Ad5FGF-4, alferminogene tadenovec)</td>
<td>Factor-based therapy</td>
<td>Single intracoronary infusion</td>
<td>Stable angina, not suitable for revascularization</td>
<td>ASPIRE (NCT01550614) aims to enroll 100 patients from Russia. Primary trial outcome is change in reversible perfusion defect size as measured by SPECT. Other outcomes include angina frequency and quality of life. Completion is expected in May 2013 [103].</td>
</tr>
<tr>
<td>3</td>
<td>CryoLife, GA, USA</td>
<td>Bone marrow-derived mononuclear cells and transmyocardial revascularization</td>
<td>Autologous bone marrow mononuclear cells and transmyocardial revascularization</td>
<td>Transmyocardial percutaneous injection</td>
<td>Refractory angina, not suitable for revascularization</td>
<td>PHOENIX (NCT01285297) aims to enroll 30 patients from Spain. Primary trial outcomes are major cardiac and cerebral events, and all-cause mortality. Other outcomes include exercise tolerance [104]. Final data collection was expected in December 2011. No trial results have been identified.</td>
</tr>
<tr>
<td>4</td>
<td>Barts Health NHS Trust, UK (lead center)</td>
<td>Bone marrow-derived mononuclear cells</td>
<td>Autologous bone marrow mononuclear cells</td>
<td>Single intracoronary reinfusion during PCI</td>
<td>Following acute myocardial infarction with LVEF ≤45%</td>
<td>BAMI trial (NCT01569178) aims to enroll 3000 patients from across Europe. This study is not yet open for recruitment. Completion is expected in January 2017 [105].</td>
</tr>
<tr>
<td>5</td>
<td>Meshalkin Research Institute of Pathology of Circulation, Russia</td>
<td>Bone marrow-derived mesenchymal stem cells</td>
<td>Autologous bone marrow mesenchymal stem cells with CABG</td>
<td>Targeted intramyocardial injection</td>
<td>Following acute myocardial infarction</td>
<td>ESTIMATION (NCT01394432) aims to enroll 50 patients from Russia. Completion is expected in November 2013 [106].</td>
</tr>
<tr>
<td>6</td>
<td>Ministry of Health, Brazil</td>
<td>Bone marrow-derived mononuclear cells</td>
<td>Autologous bone marrow mononuclear cells</td>
<td>Intracoronary infusion</td>
<td>Following acute myocardial infarction, LVEF ≤50%</td>
<td>MiHeart-AMI (NCT00350766) aimed to enroll 300 patients. Completion was expected in July 2010 [23,107]. No publicly available results were identified in February 2013.</td>
</tr>
<tr>
<td>7</td>
<td>Royan Institute, Iran</td>
<td>CD133+ cells</td>
<td>Autologous CD133+ bone marrow cells with CABG</td>
<td>Intramyocardial injection</td>
<td>Following acute myocardial infarction with indication for CABG, LVEF &lt;45%</td>
<td>NCT01167751 enrolled 27 patients. Trial results have been published [27,28].</td>
</tr>
<tr>
<td>8</td>
<td>University of Rostock, Germany</td>
<td>CD133+ cells</td>
<td>Autologous CD133+ bone marrow cells with CABG</td>
<td>Intramyocardial injection</td>
<td>Previous myocardial infarction, LVEF &gt;25 and &lt;50%</td>
<td>PERFECT (NCT00950274) aims to enroll 142 patients. Completion is expected in December 2013 [108].</td>
</tr>
<tr>
<td>9</td>
<td>Cardio3 BioSciences, Belgium</td>
<td>C-Cure® bone marrow-derived mesenchymal–cardiopoietic cells</td>
<td>Autologous bone marrow cardiopoietic cells</td>
<td>Intramyocardial injection</td>
<td>Ischemic heart failure with LVEF ≤30%</td>
<td>CHART-1 (NCT01768702) aims to enroll 240 participants in Belgium. Completion is expected in March 2017 [109].</td>
</tr>
</tbody>
</table>

CABG: Coronary artery bypass grafting; CCS: Canadian Cardiovascular Society; DCM: Dilated cardiomyopathy; LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association; PCI: Percutaneous coronary intervention; SPECT: Single-photon emission computed tomography.
Table 1. Cellular and factor-based therapies in Phase III clinical trials (cont.).

<table>
<thead>
<tr>
<th>No.</th>
<th>Company or research unit</th>
<th>Therapy</th>
<th>Therapy type</th>
<th>Delivery</th>
<th>Indication(s)</th>
<th>Additional Phase III trial information</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Meshalkin Research Institute of Pathology of Circulation, Russia</td>
<td>Bone marrow-derived mononuclear stem cells or peripheral blood stem cells</td>
<td>Autologous bone marrow mononuclear stem cells or peripheral blood stem cells</td>
<td>Targeted intramyocardial injection</td>
<td>Ischemic-related heart failure with reduced LVEF</td>
<td>ESCAPE (NCT00841958) aimed to enroll 250 patients in Russia. Primary completion was anticipated in December 2011 [111]. No publicly available trial results were identified in February 2013.</td>
</tr>
<tr>
<td>11</td>
<td>Ministry of Health, Brazil</td>
<td>Bone marrow-derived mononuclear cells</td>
<td>Autologous bone marrow mononuclear cells with CABG</td>
<td>Intramyocardial injection</td>
<td>Ischemic heart disease referred for CABG, LVEF &gt;25% and &lt;55%, CCS class II–IV</td>
<td>MiHeart–chronic ischemia (NCT00362388) aims to enroll 300 patients. Completion was expected in November 2008 [112]. No publicly available results were identified in February 2013.</td>
</tr>
<tr>
<td>12</td>
<td>Ministry of Health, Brazil</td>
<td>Bone marrow-derived mononuclear cells</td>
<td>Autologous bone marrow mononuclear cells</td>
<td>Intracoronary infusion</td>
<td>DCM, NYHA class III–IV, LVEF &lt;35%</td>
<td>MiHeart–DCM (NCT00333827) aims to enroll 300 patients. Completion was expected in February 2009 [113]. No publicly available results were identified in February 2013.</td>
</tr>
<tr>
<td>13</td>
<td>Ministry of Health, Brazil</td>
<td>Bone marrow-derived mononuclear cells</td>
<td>Autologous bone marrow mononuclear cells</td>
<td>Intracoronary infusion</td>
<td>Chagas cardiomyopathy, NYHA class III–IV, LVEF &lt;35%</td>
<td>MiHeart–Chagas (NCT00349271) enrolled 183 patients. Trial results have been published [31].</td>
</tr>
</tbody>
</table>

CABG: Coronary artery bypass grafting; CCS: Canadian Cardiovascular Society; DCM: Dilated cardiomyopathy; LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association; PCI: Percutaneous coronary intervention; SPECT: Single-photon emission computed tomography.
on stress single-photon emission computer tomography [103]. Two Phase IIb/III trials of alferminogene tadenovec (AGENT-3 and AGENT-4) were stopped early when interim analysis of one trial revealed that the study was unlikely to yield statistically significant results [17]. The primary end point was exercise tolerance at 12 weeks. Large and significant placebo effects were found in each trial. A pooled analysis of the Phase IIb/III results suggested that, for a high-dose group there were significant changes in the Canadian Cardiovascular Society angina scale and statistically significant gender differences [17].

CryoLife (GA, USA) are trialing the combination delivery of transmyocardial laser revascularization and autologous bone-marrow derived mononuclear cells. The PHOENIX Phase III trial aims to enroll 30 patients with refractory angina who are not suitable for a percutaneous coronary intervention [104]. In a single-arm, open-label study, the system appeared to provide efficient delivery of concentrated autologous bone marrow-derived mononuclear cells and resulted in reduced angina class (mean ± SD: 3.4 ± 0.5 vs 1.4 ± 0.6; p = 0.004), monthly medication use (mean ± SD: 348 ± 118 vs 201 ± 92; p = 0.001) and cardiac-related hospital readmissions (mean ± SD: 2.9 ± 2.3 vs 0.5 ± 0.8; p < 0.001) in 19 participants [18]. Although the efficacy of transmyocardial laser revascularization has not been adequately proven, it is hypothesised to enhance homing of cells and stem cell paracrine effects [19,20].

Following myocardial infarction

A large multicenter Phase III trial of intracoronary infusion of autologous bone marrow-derived mononuclear cells following myocardial infarction is in the final planning stages. The BAMI study plans to enroll 3000 patients following myocardial infarction with a reduced LVEF and significant regional wall motion abnormality 3–6 days after reperfusion therapy [105]. The primary outcome will be time to death; secondary outcomes include cardiac mortality, cardiac-related hospitalizations and adverse events. The trial builds on results from smaller Phase II studies including REPAIR-AMI, a trial of intracoronary infusion of bone marrow-derived progenitor cells in 204 patients 3–7 days after successful infarct reperfusion therapy. At 4 months the primary end point of absolute improvement in global LVEF was significantly greater with cell therapy than placebo (mean increase ± SD: 5.5 ± 7.3% vs 3.0 ± 6.5%; p = 0.01) [21]. At 2 years the cumulative end point of death, myocardial infarction and the need for revascularization was significantly reduced with cell therapy (hazard ratio: 0.58; 95% CI: 0.36–0.94; p = 0.025) [22].

The ESTIMATION Phase III study will assess the efficacy of intramyocardial injection of autologous bone marrow-derived mesenchymal stem cells in combination with CABG in 50 patients following acute myocardial infarction [106]. The trialists aim to include patients approximately 7–10 days after percutaneous coronary intervention. The primary end point is reduction in left ventricular systolic volume measured by MRI. Secondary end points include mortality, thromboembolic events, hospitalization for heart failure and exercise tolerance. The MiHeart-AMI study in Brazil aimed to recruit 300 patients and administer autologous bone marrow-derived mononuclear stem cells approximately 5–7 days after reperfusion therapy [107]. The primary end point is a change in LVEF at 6 and 12 months. Other end points include major cardiovascular events and quality of life [23].

CD133+ cells are highly proliferative primitive hematopoietic progenitor cells that can be isolated from samples of bone marrow-derived mononuclear cells. The use of CD133+ cells in combination with CABG is supported by encouraging results from early trials that have reported an increase in LVEF [24,25]. CD133+ cells have also been used in trials by intracoronary administration in the week following myocardial infarction [26].

A Phase III randomized trial of autologous bone marrow-derived CD133+ cells in patients following myocardial infarction was completed at the Royan Institute, Iran. In the study 27 participants with a recent myocardial infarction (18–90 days postinfarction) and LVEF <45% underwent CABG and an intramyocardial injection of autologous bone marrow-derived CD133+ cells or CABG alone. The primary end point was change in LVEF. At 6 months there was no difference in LVEF, however the wall motion score index was significantly reduced for akinetic and dyskinetic segments (p < 0.006) with cellular therapy [27]. At 5 years there was no statistically significant difference in LVEF; however, the improvement in wall motion score index was sustained [28].

The PERFECT Phase III trial is also investigating the intramyocardial injection of CD133+ cells in combination with CABG in a planned 142 patients following myocardial infarction who have an indication for surgical revascularization and a reduced global LVEF (between 25
and 50%) [29,108]. The primary end point will be LVEF at 6 months. Secondary end points include exercise capacity, angina class, hospitalizations and mortality.

**Ischemia-related heart failure**

Cardio3 BioSciences are sponsoring a Phase III European trial (CHART-1) of C-Cure autologous bone marrow-derived mesenchymal cardiopoitic cells in 240 patients with New York Heart Association (NYHA) class III or IV ischemic heart failure who are not in need of revascularization [109]. The mesenchymal stem cells are reprogrammed to become precursors of cardiac muscle cells – cardiopoitic cells – and administered by intramyocardial injection. The primary trial outcome is a composite of mortality; worsening heart failure, as measured by hospitalizations, transplantations, myocardial infarctions and strokes; quality of life; exercise tolerance; and change in left ventricular function at 38 weeks. Secondary safety and efficacy outcomes were measured at 52 and 104 weeks postinjection. Phase II results in 45 patients found a significant increase in LVEF with C-Cure compared with the control group (mean ± SD: 5.2 ± 0.6% vs 1 ± 0.7%; \( p < 0.01 \)) [110]. Exercise tolerance was significantly increased at 6 months post-therapy.

The ESCAPE study assessed the efficacy of intramyocardial autologous bone marrow mononuclear stem cells or peripheral blood stem cells in 250 patients with CVD, low ejection fraction and signs of heart failure. The primary study outcome was survival in the cell group compared with a medical control group [111]. Study completion was anticipated in December 2011. No publicly available results were identified.

The MiHeart-chronic ischemia study in Brazil aimed to recruit 300 patients with severe heart failure referred for CABG and administer autologous bone marrow-derived stem cells [112]. The primary end point is a change in LVEF. Other end points include major cardiovascular events and quality of life. No publicly available results were identified.

**Discussion**

Most of the identified cell-based therapies are in development to mitigate the effects of acute and chronic ischemic heart disease and involve the administration of autologous bone marrow-derived stems cells. Although the majority of techniques and products are in early-phase trials, 13 are in Phase III. However, of these 13, six are in development in Iran, Russia and Brazil, which may indicate that even if efficacy is demonstrated, licensing and availability in Europe may be delayed. Most of the approaches in Phase III trials have some evidence of possible benefit from earlier-phase trials; except for alferminogene tadenovec (Supplementary Tables 1 & 2). The factor-based approach in Phase III trials is unsupported by evidence from earlier trials.

The majority of techniques and products the authors identified use autologous cells. These cells are more acceptable from a patient perspective, have fewer associated adverse effects and are more easily regulated; however, from a commercial perspective they are less desirable owing to personalized manufacturing requirements and scientific complexities. It is therefore not surprising that there are few commercially driven developments in this field; autologous approaches offer little opportunity for commercial gain and allogenic approaches, although offering potential benefits, have unanswered questions about their immune status.

The choice of end points in regenerative medicine trials for CVD is of importance for patients, professionals and those assessing clinical effectiveness and cost-effectiveness. Study primary outcomes in the majority of Phase III trials that were identified include left ventricular function, exercise tolerance and mortality. Although surrogate end points such as left ventricular function may be helpful in assessing whether cellular therapy is efficacious, they are unlikely to be very helpful in discussions with patients and funders about likely future impacts on morbidity and activities of daily living. Although secondary outcomes for current Phase III studies include more patient-centered outcomes such as episodes of angina, major cardiac events such as reinfarction and restenosis requiring revascularization, and episodes of heart failure, many of the studies are unlikely to be powered to identify significant changes in these measures.

This review is the first that has attempted to identify the range of emerging regenerative medicine techniques and products for CVD and investigate their stage of development. The products identified employed a range of techniques, but none had all the elements of the ideal cardiac regenerative therapy suggested by Ptaszek et al. [11].

In planning how to evaluate and implement regenerative medicines, health policymakers will need to understand the intricacies of the products, the range of approaches being researched in the field and the implications of each approach. Although the majority of
approaches to regenerative medicine the authors identified were stem cell transplants, a few may be regulated as advanced therapy medicinal products by the EMA [30]. Advanced therapy medicinal products, as defined in Directive 2001/83/EC, include gene therapy medicinal products, somatic stem cell medicinal products and tissue-engineered products [113].

This review was conducted using only publicly accessible information and some information provided by univerCellmarket [102]. Neither companies nor investigators were systematically contacted to find information on ongoing development, progress with clinical trials, trial outcomes or to confirm European launch and licensing plans. It is likely that some of the techniques and products identified will no longer be in development, and it is probable that some of the research centers identified as active in this field are no longer involved in this research. It is also possible that the authors have missed some trials, particularly as keywords relating to regenerative medicine seem to be used in an arbitrary manner.

A significant complication arose in how to categorize research activity in relation to trials involving bone marrow-derived mononuclear cells particularly with collaborators in the emerging BAMI trial. Twenty-one centers within Europe are listed as collaborators in the BAMI trial, some of which are included in Supplementary Table 1 as being research active in this field.

### Executive summary

**Aim**
- The aim of this review was to identify emerging applications of regenerative medicine that have the potential to benefit patients with cardiovascular disease and to investigate their stage of development.

**Methods**
- We identified appropriate contacts and organizations in the UK and undertook a detailed online search to identify developments throughout the world. We searched clinical trial databases to gather information on products closer to licensing or launch.

**Results**
- We identified 49 Phase II, II/III and III clinical trials of regenerative medicine techniques for a range of cardiovascular diseases. Thirteen of these trials are Phase III, eight are Phase II/III and 28 are Phase II trials.
- The majority of techniques and products are in development for acute myocardial infarction and myocardial ischemia, and involve an intracoronary infusion or intramyocardial injection of autologous bone marrow-derived stem cells. We also identified two autologous cellular products in Phase II trials and three factor-based therapy products (one in Phase III and two in Phase II clinical trials).
- Most of the approaches in Phase III trials have some evidence of possible benefit from earlier-phase trials.

**Conclusion**
- Despite ongoing research activity, translation into clinical practice appears to be some way off. There is also as of yet no agreement on the most beneficial cell type; the timing of cell harvest, preparation and isolation; or the optimal method, timing or site for delivery of cellular or factor-based therapy.

**Future perspective**
- Although regenerative medicine may eventually offer a new, additional or complementary treatment option for patients with cardiovascular diseases, its exact clinical role has yet to be defined. As with all new treatments, rigorous clinical trials are required to determine efficacy, safety and effective delivery methods, and research is still required to understand whether current knowledge will translate into clinical applications.
Regenerative medicine techniques in cardiovascular disease: where is the horizon?

ongoing scientific discovery and collaboration between basic and translational researchers, commercial interests, the clinical community, health services and governments. Even following positive clinical trials proving efficacy and safety, many issues remain to be addressed, including cell storage and safety, regulation and legislation, ethical implications (although these are reduced with the use of autologous cells), economic evaluation, reimbursement and other funding issues.

Although regenerative medicine may eventually offer a new, additional or complementary treatment option for patients with CVDs, its exact clinical role has yet to be defined. Like all new treatments rigorous clinical trials are required to determine efficacy, safety and effective delivery methods. The development of commercially viable therapies will be complex and research is still required to understand how current knowledge will translate into clinical applications. Consideration is also needed as to how these techniques will fit in the innovation pathway, how evaluating bodies will appraise regenerative interventions, and how they will be funded, delivered and commissioned. The identification of techniques and products on the horizon such as that undertaken in this review will help policymakers plan for the evaluation and adoption of successful therapies by health services.

Disclaimer
The NIHR did not participate in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Financial & competing interests disclosure
The National Institute for Health Research Horizon Scanning Centre is a research program funded by the National Institute for Health Research (NIHR). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Open Access
This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

References
Papers of special note have been highlighted as:
* of interest
** of considerable interest

5 * Describes the UK’s leading position in the regenerative medicine field and the current regulatory system, and the challenges that the UK is likely to face in relation to regenerative medicines.
6 * Describes the current position of the UK in the regenerative medicine field and identifies eight strategic objectives that will need to be addressed to make the most of its current position and to overcome the obstacles that those developing regenerative medicine technologies are likely to face.
14 Hare JM, Fishman JE, Gerstenblith G et al. Comparison of allogeneic vs autologous bone-marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy. The POSEIDON randomized trial. JAMA 308(22), 2369–2379 (2012).
16 * Update of a previous article (published in 2008) that reviewed randomized controlled trials comparing autologous stem/progenitor cells with no autologous stem/progenitor cells in patients diagnosed with acute myocardial infarction.
18 Reyes G, Allen KB, Alvarez P et al. Mid term results after bone marrow laser...


** Websites**


* Sets standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.